Diabetic nephropathy: A historical, clinical and diagnostic framework;La nefropatia diabetica: Inquadramento storico, clinico e diagnostico

Minerva Medica

Volumn 93, Issue 5, 2002, Pages 347-355

  Conti, A A ^a,b  

^a UNIVERSITY OF FLORENCE   (Italy)

^b IRCCS FONDAZIONE DON CARLO GNOCCHI   (Italy)

Author keywords

Albuminuria; Cardiovascular diseases; Diabetic nephropathies, diagnosis; Evidence based medicine; History of medicine

Indexed keywords

ALBUMIN; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT;

CARDIOVASCULAR DISEASE; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DISEASE COURSE; EVIDENCE BASED MEDICINE; HUMAN; HYPERTENSION; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY FAILURE; KIDNEY FUNCTION; NON INSULIN DEPENDENT DIABETES MELLITUS; PROGNOSIS; PROTEINURIA; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW;

ALBUMINURIA; BASEMENT MEMBRANE; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DISEASE PROGRESSION; HUMANS; KIDNEY; KIDNEY GLOMERULUS; PROGNOSIS; RISK FACTORS;

EID: 0036818448     PISSN: 00264806     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (67)

1. Remuzzi G, Bertani T. Pathophysiology of progressive nephropathities. N Engl J Med 1998;339:1448-56.
2. Renal Data System. USRDS 1998 Annual Data Report. Bethesda, Md. National Institute of Diabetes and Digestive and Kidney Diseases. April 1998 (NIH publication no. 98-3176).
3. Ritz E, Rychlik I, Locatelli F, Halimi S. End-stage renal failure in type 2 diabetes: Medical catastrophe of worldwide dimensions. Am J Kidney Dis 1999;34:795-808.
4. Warram JH, Freire MB. Epidemiology of late diabetic complications. A basis for the development and evaluation of preventive programs. Endocrinol Metab Clin North Am 1996;25:217-42.
5. Bright R. Cases and observations illustrative of renal disease accompanied with the secretion of albuminous urine. Guy's Hospital Report 1836;10:338-40.
6. Kimmelstiel P, Wilson C. Intercapillary lesions in the glomeruli in the kidney. Am J Pathol 1936; 12:83-97.
7. Bell DS, Alele J. Dealing with diabetic nephropathy. Postgrad Med 1999;105:83-7.
8. Ritz E, Stefanski A. Diabetic nephropathy in type II diabetes. Am J Kidney Dis 1996;27:167-94.
9. Remuzzi G, Ruggenenti P. Slowing down the progression of diabetic nephropathy N Engl J Med 1993;329:1496-7.
10. Mogensen CE. Progression of nephropathy in long-term diabetics with proteinuria and effect of initial antihypertensive treatment. Scand J Clin Lab Invest 1976;36:383-8.
11. th ed. Philadelphia: WB Saunders; 1996. vol 2. p. 1864-92.
12. Pettitt DJ, Saad MF, Bennett PH, Nelson RG, Knowler WC. Familial predisposition to renal disease in two generations of Pima Indians with type 2 (non-insulin-dependent) diabetes mellitus. Diabetotogia 1990;33:438-43.
13. Cowie CC, Port FK, Wolfe RA, Savage PJ, Moll PP, Hawthorne VM. Disparities in incidence of diabetic end-stage renal disease according to race and type of diabetes. N Engl J Med 1989;321:1074-9.
14. Keller CK, Bergis KH, Fliser D, Ritz E. Renal findings in patients with short-term type 2 diabetes. J Am Soc Nephrol 1996;7:2627-35.
15. Strojek K, Grzeszczak W, Morawin E, Adamski M, Lacka B, Rudzki H et al. Nephropathy of type 2 diabetes: Evidence for hereditary factors? Kidney Int 1997;51:1602-7.
16. Tarnow L, Gluud C, Parving H-H. Diabetic nephropathy and the insertion/deletion potymorphism of the angiotensin-converting enzyme gene. Nephrol Dial Transplant 1998;13:1125-30.
17. Jeffers BW, Estacio RO, Raynolds MV, Schrier RW. Angiotensin-converting enzyme gene polymorphism in non-insulin dependent diabetes mellitus and its relationship with diabetic nephropathy. Kidney Int 1997;52:473-7.
18. Blutbner M, Schmidt S, Siffert W, Knigge H, Nawroth P, Ritz E. Increased frequency of G-protein Beta3-subunit 825 T allele in dialyzed patients with type 2 diabetes. Kidney Int 1999;55:1247-50.
19. Ibrahim HA, Vora JP. Diabetic nephropathy. Baillieres Clin Endocrinol Metab 1999;13:239-64.
20. Allen TJ, Cooper ME, Gilbert RG, Winikoff J, Skinner SL, Jerums G. Serum total renin is increased before microalbuminuria in diabetes (IDDM). Kidney Int 1996;50:902-7.
21. Kelly DJ, Wilkinson-Berka JL, Allen TJ, Cooper ME, Skinner SL. A new model of diabetic nephropathy with progressive renal impairment in the transgenic (mRen-2) 27 rat (TGR). Kidney Int 1998;54:343-52.
22. Olivarius N de F, Andreasen AH, Keiding N, Mogensen CE. Epidemiology of renal involvement in newly-diagnosed middle-aged and elderly diabetic patients: Cross-sectional data from the population-based study "Diabetes Care in General Practice", Denmark. Diabetologia 1993;36:1007-16.
23. Ravid M, Brosh D, Ravid Safran D, Levy Z, Rachmani R Main risk factors for nephropathy in type 2 diabetes mellitus are plasma cholesterol levels, mean blood pressure, and hyperglycemia. Arch Intern Med 1998; 158:998-1004.
24. Biesenbach G, Janko O, Zazgomik J. Similar rate of progression in the predialysis phase in type I and type II diabetes mellitus. Nephrol Dial Transplant 1994;9:1097-102.
25. Sawicki PT, Didjurgeit U, Muhlhauser I, Bender R, Heinemann L, Berger M. Smoking is associated with progression of diabetic nephropathv. Diabetes Care 1994;17:126-31.
26. Toeller M, Buyken A, Heitkamp G, Bramswig S, Mann J, Milne R et al. Protein intake and urinary albumin excretion rates in the EURODIAB IDDM Complications Study. Diabetologia 1997;40:1219-26.
27. Zeller K, Whittaker E, Sullivan L, Raskin P, Jacobson HR. Effect of restricting dietary protein on the progression of renal failure in patients with insulin-dependent diabetes mellitus. N Engl J Med 1991;324:78-84.
28. Bowden DW, Sale M, Howard TD, Qadri A, Sprav BJ, Rothschild CB et al. Linkage of genetic markers on human chromosomes 20 and 12 to NIDDM in Caucasian sib pairs with a history of diabetic nephropathy, Diabetes 1997;46:882-6.
29. nd Ed. Bethesda, MD: National Institutes of Health; 1995. p. 429-48.
30. Ismail N, Becket B, Strzelczyk P, Ritz E Renal disease and hypertension in non-insulin-dependent diabetes mellitus. Kidney Int 1999;55:1-28.
31. Mogensen CE. Microalbuminuria, blood pressure and diabetic renal disease: Origin and development of ideas. Diabetotogia 1999;42:263-85.
32. DCCT. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of tong-term complications in insulin-dependent diabetes metlitus. N Engl J Med 1993;329:977-86.
33. DCCT. The Diabetes Control and Complications Trial Research Group. The absence of a glycemic threshold for the development of long-term complications: The perspective of the Diabetes Control and Complications Trial. Diabetes 1996;45:1289-98.
34. DCCT. The Diabetes Control and Complications Trial Research Group. Influence of intensive diabetes treatment on quality-of-life outcomes in the diabetes control and complications trial. Diabetes Care 1996;19:195-203.
35. De Francisco AL. Clinical outcomes for patients with diabetic nephropatby. EDTNA ERCA J 1999;25:23-7.
36. th Ed. Philadelphia: WB Saunders Company; 1998.
37. Lewis JB. Diabetic nephropathy in patients with type II diabetes. Geriatr Nephrol Urol 1999;9:167-75.
38. th Ed. New York: McGraw-Hill; 2001.
39. Andersen AR, Christiansen JS, Andersen JK, Kreiner S, Deckert T. Diabetic nephropathy in type 1 (insulin-dependent) diabetes: An epidemiological study. Diabetologia 1983;25:496-501.
40. Colweli M, Halsev JF. High incidence of false-positive albuminuria results with the Micro-Bumintest. Clin Chem 1989;35:1252-4.
41. Tiu SC, Lee SS, Cheng MW. Comparison of six commercial techniques in the measurement of microalbuminuria in diabetic patients. Diabetes Care 1993;16:616-20.
42. Al-Kassab AS. Evaluation of a simple method for the screening of microatbuminuria in diabetic patients. Scand J Clin Lab Invest 1990;50:913-5.
43. Hutchinson AS, O'Reilly DS, MacCuish AC. Albumin excretion rate, albumin concentration, and albumin/creatinine ratio compared for screening diabetics for slight albuminuria. Clin Chem 1988;34:2019-21.
44. Sawicki PT, Heinemann L, Berger M. Comparison of methods for determination of microalbuminuria in diabetic patients. Diabetes Med 1989;6:412-5.
45. Connelt SJ, Hollis S, Tieszen KL, McMurray JR, Dotnan TL. Gender and the clinical usefulness of the albumin: Creatinine ratio. Diabetes Med 1994;11:32-6.
46. Poulsen PL, Mogensen CE. Clinical evaluation of a test for immediate and quantitative determination of urinary albumin-to-creatinine ratio. A brief report. Diabetes Care 1998;21:97-8.
47. Parsons M, Newman DJ, Pugia M, Newali RG, Price CP. Performance of a reagent strip device for quantiration of the urine albumin: Creatinine ratio in a point of care setting. Clin Nephrol 1999;51:220-7.
48. NHS Centre for Reviews and Dissemination. Complications of diabetes: Renal disease and promotion of self-management. Effective Health Care 2000;6:1-12.
49. th Ed. Boston/Toronto/London: Little, Brown and Co.; 1993.
50. th Ed. Philadelphia: WB Saunders; 1991.
51. Gall MA, Borch-Johnsen K, Hougaard P, Nielsen FS, Pawing HH. Albuminuria and poor glycemic control predict mortality in NIDDM. Diabetes 1995;44:1303-9.
52. Dinneen SF, Gerstein HC. The association of microalbuminuria and mortality in non-insulin-dependent diabetes mellitus - A systematic overview of the literature. Arch Intern Med 1997;157:1413-8.
53. Wang SL, Head J, Stevens L, Fuller JH. Excess mortality and its relation to hypertension and proteinuria in diabetic patients: The World Health Organization Multinational Study of Vascular Disease in Diabetes. Diabetes Care 1996;19:305-12.
54. Ahmad J, Siddiqui MA, Ahmad H. Effective postponement of diabetic nephropathy with enalapril in normotensive type 2 diabetic patients with microalbuminuria. Diabetes Care 1997;20:1576-81.
55. Bakris GL, Weir MR, DeQuattro V, McMahon FG. Effects of an ACE inhibitor/calcium antagonist combination on proteinuria in diabetic nephropathy. Kidney Int 1998;54:1283-9.
56. Bell DS, Alele J. Dealing with diabetic nephropathy. Postgrad Med 1999;105:83-7.
57. Agardh CD, Garcia-Puig J, Charbonnel B, Angelkort B, Barnett AH. Greater reduction of urinary albumin excretion in hypertensive type II diabetic patients with incipient nephropathy by lisinopril than by nifedipine. J Hum Hypertens 1996;10:185-92.
58. De Cesaris R, Ranieri G, Andriani A, Lamontanara G, Cavallo A, Bonfantino MV et al. Effects of benazepril and nicardipine on microalbuminuria in normotensive and hypertensive patients with diabetes. Clin Pharmacol Ther 1996;60:472-8.
59. Lovell HG. Are angiotensin converting enzyme inhibitors useful for normotensive diabetic patients with micro-albuminuria? The Cochrane Library. Oxford: Update Software; 1999.
60. HOPE. The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converring-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000;342:145-53.
61. Lewis EJ, Hunsicker LG, Clarke WR, Bed T, Pohl MA, Lewis JB et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001;345:851-60.
62. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Pawing H-H et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001;345:861-9.
63. Parving H-H, Lehnert H, Brochner-Mortensen J, Gomis R, Andersen S, Arner P. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001;345:870-8.
64. McGowan T, McCue P, Sharma K. Diabetic nephropathy. Clin Lab Med 2001;21:111-46.
65. Raptis AE, Viberti G. Pathogenesis of diabetic nephropathy. Exp Clin Endocrinol Diabetes 2001;109 Suppl 2:S424-37.
66. Makino H, Shikata K, Wada J. Diagnosis and treatment of diabetic nephropathy. Nippon Naika Gakkai Zasshi 2001;90:350-8.
67. Ritz E, Orth SR. Nephropathy in patients with type 2 diabetes mellitus. N Engl J Med 1999;341:1127-33.